According to current NAEPP (2020 focused update) asthma guidelines for adults, which represents the correct stepwise pharmacologic approach for persistent asthma?

Question

Accepted Answer

✅ C. Short-acting beta agonist (SABA) for rescue → add low-dose inhaled corticosteroid (ICS) as a controller → step up to ICS/LABA combination → add LAMA or biologic therapy for severe disease
This is the correct NAEPP 2020 stepwise sequence. Step 1 (intermittent): SABA as needed (albuterol). Step 2 (mild persistent): add a daily low-dose ICS controller such as fluticasone, budesonide, or beclomethasone; SMART therapy (ICS-formoterol used both as controller and as reliever) is now preferred at steps 3-4. Step 3 (moderate persistent): low-dose ICS plus LABA, or medium-dose ICS. Step 4 (severe persistent): medium-to-high dose ICS/LABA combination. Step 5-6: add a long-acting muscarinic antagonist (tiotropium) and consider biologics targeting specific pathways (omalizumab for IgE-high allergic asthma, mepolizumab/benralizumab/reslizumab for eosinophilic asthma, dupilumab for type-2 high asthma). Oral corticosteroids are reserved for exacerbations or the most severe refractory disease.

❌ A. Long-acting beta agonist (LABA) monotherapy → add inhaled corticosteroid → add oral corticosteroid → add SABA
LABA monotherapy is CONTRAINDICATED in asthma (FDA black-box warning — increased risk of asthma-related death). A LABA must always be combined with an ICS. Also, SABA is rescue therapy, not an add-on to chronic controller therapy.

❌ B. Oral corticosteroid → inhaled corticosteroid → LABA → SABA
Chronic oral corticosteroids cause systemic toxicity (osteoporosis, hyperglycemia, adrenal suppression, weight gain, cataracts) and are reserved for severe refractory asthma or short courses during exacerbations. Inhaled therapy is always preferred over systemic for chronic control.

❌ D. Leukotriene receptor antagonist (montelukast) monotherapy → add SABA → add ICS → add biologic
Montelukast has a BLACK-BOX warning (2020, FDA) for neuropsychiatric adverse effects (agitation, depression, suicidal ideation) and is NOT first-line controller therapy. It is a second-line or add-on agent for patients with concomitant allergic rhinitis or exercise-induced bronchospasm who cannot tolerate ICS.

:::important
NAEPP asthma pearls: (1) Never use LABA monotherapy (black-box). (2) SABA alone without a controller is no longer recommended for mild persistent asthma — add low-dose ICS even at step 2. (3) SMART therapy (ICS-formoterol used both as daily controller and rescue) is preferred at steps 3-4 over traditional SABA rescue. (4) Montelukast has a neuropsychiatric black-box warning and is not first-line.
:::

Asthma/COPD Medications

📖 Overview

⚙️ Mechanism of Action

💎 Board Pearls

💊 Drugs in This Class

Practice Questions

Sources

Ready to practice?